SSS 07Alternative Names: anti-tumour necrosis factor monoclonal antibody - 3SBio/Apexigen; APX-001; humanised TNF alpha monoclonal antibody - 3SBio/Apexigen; SSS-07
Latest Information Update: 25 Jun 2015
At a glance
- Originator Epitomics
- Developer 3SBio
- Class Monoclonal antibodies
- Mechanism of Action Tumour necrosis factor inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Rheumatoid arthritis
- Preclinical Autoimmune disorders; Psoriasis